3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
10
Neoplasms
9
Carcinoma
6
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasm Metastasis
3
Melanoma
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Lung Neoplasms
2
Kidney Diseases
2
Glioblastoma
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
cT2a N0NxM0 Renal Tumor
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors
1
Solid Malignancies
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
1
Prostatic Neoplasms
1
Interventions
Cisplatin
30
Pemetrexed
21
Gemcitabine
11
Radiotherapy
6
Nivolumab
6
Drug Therapy
6
Cyclophosphamide
6
Carboplatin
6
durvalumab
4
Vinorelbine
4
Chemotherapy, Adjuvant
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
sodium thiosulfate
3
sargramostim
3
Ipilimumab
3
Doxorubicin
3
raltitrexed
2
pembrolizumab
2
cediranib
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Psychiatric Rehabilitation
2
Photochemotherapy
2
Neoadjuvant Therapy
2
Methotrexate
2
Interferon-alpha
2
Imatinib Mesylate
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma, Malignant
×
Axitinib
×
Clear all
NCT01211275
2017-02-28
N08CPA
The Netherlands Cancer Institute
Phase 1/2
Completed
32 enrolled